IMPORTANCE OF NANOCARRIERS AND PROBIOTICS IN THE TREATMENT OF ULCERATIVE COLITIS

VANDANA THAKUR1, BHUPENDRA SINGH1, ANKITA SHARMA1, NISHA KUMARI1, INDER KUMAR2, KRITIKA VERMA2, ARVIND KUMAR2, SUSHMITA RANA2
1 Abhilashi College of Pharmacy, Ner Chowk, Mandi, Himachal Pradesh, India; 2 School of Pharmacy, Abhilashi University, Mandi, Himachal Pradesh, India
Email: vandnathakur129@gmail.com

Received: 18 Mar 2020, Revised and Accepted: 21 Oct 2020

INTRODUCTION

IBD is a disease of the gastrointestinal tract and it is identified by unrestricted inflammation caused by unsuitable and constant action of the mucosal immune system. Ulcerative colitis and Crohn’s disease are the different types of inflammatory bowel disease (IBD), which are very common, with associated significant morbidity and mortality [1,2]. While the main reasons are mostly undetermined, the pathogenesis of IBD but the factors related to the environment and genetic vulnerability are found to be associated with IBD. Ulcerative colitis is chronic inflammatory disorders found in the intestinal tract that causes the life-threatening issue and have an increasing occurrence worldwide [4]. The small intestine and large intestine or colon are the major areas involved in the IBD, which are manifested by the persistent inflammation in certain areas of the mucosa [5]. It is determined by intermittent rectal bleeding, diarrhea, rectal urgency, and tenesmus [6]. Molodecky et al. (2010) studied In Western Europe, Asia, and North America, this disease has an annual occurrence of approximately 24.3 per 100,000 populations every year, 6.3 per 100,000 per year, and 19.2 per 100,000 populations every year, respectively. IBD is becoming a world disorder because of its increasing occurrence and prevalence of it concerning time. There is a very lower occurrence in Africa, South America, and Asia [7]. It has been predicted that more than 1 million individuals suffer from IBD in the US, out of which 100,000 are children. IBD is in 5th rank amid the most common gastrointestinal disorder.

Epidemiology

The occurrence and prevalence of ulcerative colitis have been expanding over time worldwide. Ulcerative colitis is mainly related to recurrent attacks with complete remission of symptoms. Kim et al. (2017) studied show the increased incidence of the disease is more (three to six-fold more) in Jewish and it is more common in Caucasians than in black. In Western Europe occurrence of approximately 6 to 8 cases per 100,000 populations and the USA, and an estimated occurrence of about 70 to 150 per 100,000 populations. Within Europe, it seems a variance in ulcerative colitis incidence; with the eastern countries have low incidence than in western and in northern countries. The possibility of progression of ulcerative colitis in children of an immigrant from low occurrence to high occurrence is the same as non-immigrants. In the world, IBD is becoming a big problem because of its increasing occurrence and widespread of its concern for time. The incidence in Africa, Asia, and South America is very low [8,9]. In the United States, it has been predicted that 100,000 children are affected by IBD in the US, out of 1 million people.

Etiology of ulcerative colitis

The precise cause of ulcerative colitis is not known, but some factors that are related to the disease, including family history, use of oral contraceptives, genetic, Gut/environmental, psychosomatic, autoimmune, epidemiological are responsible. An autoimmune condition stimulated by colonic bacteria resulting in inflammation of the gastrointestinal tract is possibly called ulcerative colitis. Family history is there in around 25-40% of children; the people about to with concerning an individual with Chron disease are 17-35 times more likely to develop ulcerative colitis than the general population. A combination of factors, including abnormal mucosal immune responses, intestinal epithelial dysfunction, and defects of host interactions with intestinal microbes, can contribute to CD [10]. Environmental factors consist of immune interactions, bacterial infections, and epithelial barrier functions. Epidemiological studies consist of nutritional behavior, smoking habits, ingestion of drugs, hormonal conditions, variations resulting from different climates, and changes due to social conditions. Hygiene theory suggests that the decline in enteric infections in developed countries has caused insufficient progress of the dictatorial processes that mucosal immune responses are bound [11]. The inflammatory factors can be investigated through different cell signal pathways, inflammatory mediators such as tumor necrosis factor α (TNF-α), Interleukin-6, Interleukin-1, Interleukin-12, Interleukin-11 and Interleukin-4, and Ricosanoids profiles [12].
Fig. 1: Etiologic factors in IBD

Chronic inflammation resulted from the production of reactive oxygen species produces dysplasia, which can turn into CAC, i.e., colitis-associated colorectal cancer, which is a critical type of ulcerative colitis. Therefore, with ulcerative colitis, the high possibility of colon cancer in patients is there[14]. The mucosal layer of the colon is the region where the inflammation is confined. The rectum is always involved, with inflammation expended proximally in a confluent fashion. In opposition, the CD is not limited to a restricted region and can be found in any part of GIT, and the inflammation can be asymmetrical, transmural, and segmented[15].

Pathophysiology of ulcerative colitis

Pathogenesis of ulcerative colitis remains unknown, in current years several some many findings conclusion point to an over incentive or insufficient regulation of the mucosal immune system as a crucial pathophysiologic pathway, and then particular emphasis can be given to the analyses of immunologic reactions of mucosal inflammation. Several factors of ulcerative colitis that result in primary immunological disorders or there are doesn’t appropriate pathological immunological reactions to an environment e. g. commensal intestinal microorganisms. The first main cause is the deregulation of the immune system, which results in uncontrolled immune responses to usual microflora.

In maximum (i.e. 95%) cases, deregulations of the immune system expend directly from the rectum in a continuous pattern involving part or every part of the colon. A second cause is the epithelial cell abnormalities and alters in the content of gut microflora that facilitates an unusual mucosal immune response[16]. A third cause is a reduced gene expression i.e., alteration of the gene that is CARD15/NOD2[17]. Ulcerative colitis is a chronic condition that contains large intestine and colon, where the entire organ or a portion of the gastrointestinal is affected by inflammation. Ulcerative Colitis is the inflammatory bowel disease which contains inflammation and ulceration which expend from the rectum towards the caecum and is normally related to extra IL-13 producing where, Crohn’s disease is related to the abundant production of IL-12/IL-23 and IFN-γ/IL-17, it usually involves part of ileum and colon where discontinuous ulceration and inflammation including granulomas occurs [18]. Fig. 2[19] shows the mechanism of UC by NF-κB mechanism. Unusually increased intestinal permeability is one of the factors that caused ulcerative colitis and that will result in disease continuation, which can be reported by some authors. Thus breaking down the barrier function of epithelial wall conduct to increase the permeability of mucosa for luminal antigens, bacteria or microorganisms, and loss of water and electrolytes by activating the inflammatory process. Due to breakage of the barrier from the epithelium water and various electrolytes have been lost Incorporation of this, the lost polarity of damaged intestinal cells that results in apical expression of the transferrin receptor protein, whose appearance is mainly increased apical
and basolateral sites of enterocytes in the inflamed mucosa of IBD patients.

**Signs and symptoms of ulcerative colitis**

The main symptoms of ulcerative colitis (UC) include pain, discomfort and diarrhea with blood (Table 1). Fever and weight loss occur sometimes. Extraintestinal symptoms can be an initial expression or can occur subsequently in the duration of the illness.

In proctitis, occasionally, obstipation can be the initial symptom. Weight loss, tachycardia, rectal bleeding, and bowel inflammation are significant symptoms. Ulcerative colitis is divided into various classes i.e., distal, extensive, ulcerative proctitis. Meier et al. (2011) have studied which briefly explains that ulcerative colitis is given in fig. 3 [20]. Around eighty percent of the patients suffer from proctitis, and extensive colitis is found in 20% of patients.

![Fig.3: A schematic diagram for ulcerative colitis](image)

| S. No. | Symptoms                        | % frequency | References |
|--------|---------------------------------|-------------|------------|
| 1.     | Diarrhoea                       | 96.4 %      | [20]       |
| 2.     | Blood in stool                  | 89.3 %      | [20]       |
| 3.     | Pain                            | 81.3 %      | [20]       |
| 4.     | Generally unwell                | 40.2 %      | [20]       |
| 5.     | Arthralgia                      | 27.7 %      | [20]       |
| 6.     | Fever                           | 20.5 %      | [20]       |
| 7.     | Weight Loss                     | 20.5 %      | [20]       |
| 8.     | Fever                           | 20.5 %      | [20]       |
| 9.     | Skin Changes                    | 20.5 %      | [20]       |
| 10.    | Loss of appetite                | 15.2 %      | [20]       |
| 11.    | Ophthalmopathies                | 7.1 %       | [20]       |
| 12.    | Nausea                          | 6.3 %       | [20]       |

Table 1: Initial symptoms of ulcerative colitis

However, proximal extension results late in around 50% of patients with proctosigmoiditis, and in other patients, the opposite occurs. A change in the area of the disorder should arise new symptoms. The duration of the disease can change.

| Drug type | Drug name | Available routes | Efficacy | Induction dose | Maintenance dose | Adverse events | Reference(s) |
|-----------|-----------|------------------|----------|---------------|------------------|----------------|--------------|
| 5-Amino Salicylate | Mesalamine | Oral Rectal | Induction and maintenance | Mesalamine: 2-4.8g (oral) | Mesalamine: 1.6-2.4g | Headache, nausea, diarrhea, interstitial nephritis, leukopenia, and hepatitis | [22,23] |
| Corticosteroids | Prednisone | Oral Rectal IV | Induction only | Prednisone: 40-60 mg | Prednisone: 1-1.5 g/kg | Delirium, cataracts, glaucoma, striae, delayed wound healing, adrenal insufficiency | [22,23] |
| Thiopurines | Azathioprine | Oral | Induction and maintenance | Azathioprine: 2-2.5 g/kg | Azathioprine: 2-2.5 g/kg | Nausea, vomiting, hepatitis, bone marrow suppression, pancreatitis | [22,23] |
| Anti-TNF | Infliximab | IV Subcutaneous | Induction and maintenance | Infliximab: 5 mg/kg every 2 weeks 0, 2, and 6 | Infliximab: 5 mg/kg every 2 weeks | Infusion/injection site reaction, infection, melanoma, reactivation of latent TB and hepatitis | [22,23] |

![Table 2: A schematic diagram for ulcerative colitis](image)
Drugs used in the management of ulcerative colitis

Ulcerative colitis relies on the extremity of the disease, its subtype, patient preference. Most frequently used drugs for its cure and management are an anti-inflammatory agent which mostly includes 5-aminosalicylates like olsalazine, mesalazine, and balsalazide, which can treat slightly to average attacks and can sustain remission in UC and immunosuppressive agents which includes azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, tacrolimus calcineurin inhibitors. Other categories of drugs include Corticosteroids, like prednisolone and anti-TNF-α antibodies for ordinary to acute or serious conditions of IBD [21]. Table 2 shows the different drugs used in the treatment of ulcerotic colitis.

Aminosaliclylates

Sulfasalazine is the first-class drug of antibiotics. For the management of ulcerotic colitis Oral 5-aminosalicylic acid (5-ASA) is taken. Mesalamine (5-ASA) is usually absorbed from the upper region of the intestine; particular delivery of drugs into the colon may be amercetable to method of drug delivery with fewerside effects and more potency. Due to side effects in those with sulfa allergy and nausea, newer forms of 5-ASA were created specific for its activity on the GI tract. The mechanism of action of 5-Amino salicylates includes the stimulation of class of nuclear receptors, which mainly include cell proliferation and inflammation. It helps in decreasing the production of proinflammatry leukotrienes and slow down the cellular release of interleukin-1 and 2 [24]. Wanget al. (2016) have studied 5-ASA Common side effects like flatulence, nausea, abdominal pain, diarrhea, headache, dyspepsia, nasopharyngitis [25]. Management of mesalamine using combination of rectal and oral provides complete relief of distal UC than rectal or oral therapy alone [26].

Corticosteroids

These drugs act via glucocorticoid receptor in the cell nucleus and immune response modulates but due to the steroidal nature of these drugs, they can improve corticoid resistance and corticoid dependency, which its maximum applicability in UC [27]. These drugs are used for mild to common conditions of UC. But in the acute type of IBD and for patients who do not show any effect to corticosteroids, Immunosuppressive drugs like azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, tacrolimus, etc. are the next line of drugs and play an important part in the treatment IBD. But the safety profile of this treatment is still an issue [28].

Thiopurines

The thiopurines, 6-MP and AZA have been said to sustain remission in UC and immunosuppressive agents which includes azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, tacrolimus, etc. are the next line of drugs and play an important part in the treatment IBD. But the safety profile of this treatment is still an issue [28].

Anti-tumor necrosis factor therapy

Infliximab is a chimeric monoclonal antibody that is used against tumor necrosis factor-alpha (TNF-α) and also used in the management of autoimmune diseases. For patients with average-to-acute UC who are intolerant of mesalazine (5-ASA) products and immune modulators, infliximab is used for remission induction. UC patients failed mesalamine and immune modulators therapy, then Infliximab can be used for management of remission in UC patients. The use of infliximab in ulcerative colitis patients whose therapy is based on steroids is unclear. Infliximab can be used in acute steroid-resistant in ulcerative colitis patients who are unwilling to undergo surgery. The cases of hepatosplenic lymphoma have been described in younger patients on infliximab who were on related immune-suppressive agents [32,33].

Challenges in the maintenance and treatment of ulcerotic colitis

Many drugs are available for the therapy of ulcerative colitis. 5-aminosalicylic acid, oral or systemic corticosteroids, immune modulator, etc. but these drugs are associated with many serious side effects after long-term use or have a certain disadvantage or not suitable for the use in some patients. Reduction of drug-related side effects is the main challenge of therapy in ulcerative colitis. [e. weight loss, rectal bleeding, anemia, tachycardia, and bowel distension by drug delivery to the colon which is site-specific [34]. Kinnet al. (2006) have studied to design a delivery system, which delivers the maximum amount of drug to the specific site at the right period time in the body that increases efficacy, compliance is a great [35]. There are numbers of agents taken for the therapy of ulcerative colitis diseases but they show adverse effects like diarrhoea, peptic ulcer, nephron and hepatotoxicity, vomiting, glaucoma, Cushing’s syndrome, etc. [36-38]. To target the drugs, particularly the colonic part of GIT is the main challenge [39]. Synthetic drugs have various drawbacks and for this reason, safe and efficacious drug treatment for the UC is the problem. The damage to skeletal and growth development is because of the absence of balanced nutrition is another problem for children with IBD. To solve these difficulties, proper nutrition and appropriate anti-inflammatory therapy are the best options.

Role of microparticles and nanocarrier ulcerative colitis

Microparticles and Nanocarrier systems are used for the targeted type of drug delivery for the management of ulcerative colitis. Microparticles are suitable for a wide variety of drug delivery applications, and they offer many advantages.

- They offer improved control over the release rate of the drug.
- They offer improved drug delivery mechanism.
- They allow the preparation of dosage forms for colon delivery through the use of coatings designed.
- They reduced particle size gives them the potential to improve bioavailability.

The major motive of this delivery system is to target the high concentration of active ingredients to the site in the inflamed intestinal tissues to enhance the therapeutic efficacy and minimizing the side effects [40]. Micro and Nanoparticle systems provide selective drug targeting to the specific site with all the needed efficacious drug dose and side effects [41]. So the formation of a novel site-specific drug delivery system that will increase the drug release in the inflamed tissues without causing any harm to normal tissues and then decrease the side effects of the drug is needed.

The major step in this direction is preparing pharmaceutical dosage forms with reduced sizes, which will enhance the time of their residence in the colon part. The most common characteristic of IBD is diarrhea that causes the streaming of the dosage form (rapid transit of large dosage forms). By decreasing the size of dosage forms (e.g. pellets) the enhancement in the retention time can be done. Further, the decrease in size to micrometer range will help to reduce the streaming effect (and thereby increase the residence time) and also helps in enhancing the bio-distribution of drug molecule [42,43]. Lately, many innovative ideas have been explored for the management of IBD. The main motive behind the development of these targeted drug delivery systems was to reach site-specific transport of active moieties to the inflamed tissue. These drug carrier systems not only prevent degradation of active moieties against various physiological changes happening during IBD but also increase the therapeutic effectiveness and lessen the incidence of systemic adverse drug reactions. Research and development in the treatment of IBD are observing steady-state
progress in terms of development of upgraded and smart drug delivery systems, and highly effective therapeutic agents. One can say that the idea of attaining effective and site-specific targeting for the treatment of IBD will soon be able to knock the doors of reality.

**Mechanism of uptake of nanocarriers/microcarriers**

The mechanism of uptake of nanocarriers/microcarriers for site-specific drug delivery is depending upon the full information of the mechanism of disease and drug. In some studies, it has been stated that for ulcerative colitis treatment, microparticles range should be 10–300 µm to target specifically to the inflamed region of the colon. Carrier selection is very important for a particular drug i.e. either hydrophilic or lipophilic and also depends on the disordered situations as well as on the physicochemical nature of the drug. The optimal particle size should be between 4 to 15 µm for improved localization and increased the residence time of the drug at the site of inflammation [44-46]. To attain high localization in Payer’s patches, intestinal lymphoid tissue, and lamina propria, there is the need to overcome such barrier/layer. In the case of UC, as the disease severity increases, the protective mucus layer starts becoming thinner. This pathophysiology of the mucus layer increases the mucosal permeability and helps in the proper location at its inflamed sites. Size-dependent translocation of MP and NP across colonocytes in the healthy GI tract contains Fig. 4.Lamprecht et al. (2001) shows that the mechanism of nanocarriers in ulcerative colitis that nanocarriers sys tems to target the inflamed mucosa are a promising strategy in ulcerative colitis treatment[46].

**Fig.4**: Show the mechanism of nanocarriers uptake in ulcerative colitis

Reducing the particle size of drug delivery systems is believed to increase colonic residence time but can also provide additional benefits for IBD therapy, such as a selective accumulation in inflamed tissues. Nanocarriers are taken up by an increased number of immune-related cells in active inflammation and to suppress inflammation via multiple pathways, like inhibiting the production of pro-inflammatory cytokines (i.e., TNF-α, IL-1β or IL-8). In some earlier studies, the different carriers system used in ulcerative colitis is shown in Table 3.

| Drug             | System used                                      | Inference                                                                 | Reference       |
|------------------|--------------------------------------------------|---------------------------------------------------------------------------|-----------------|
| 5-Aminosalicylic acid | Alginate blend microspheres Chitosan-ca-alginic acid microspheres | Increase therapeutic efficiency, mucoadhesive and controlled release. Drug targeting, biocompatible, low toxicity. | [48]            |
| Cyclosporine     | Polymeric nanocarriers Lipid nanoparticles       | Minimizing systemic exposure and associated adverse effect. Enhancing efficacy and reducing the risk of nephrotoxicity and decrease renal damage. | [52] [53]       |
| Prednisolone     | Conjugate microspheres                           | Eudragit coated Ch-SP-MS were considered potentially suitable for in vivo or practical application as a specific delivery system of PD to IBD sites. | [55]            |
| Budesonide       | Chitosan coated alginate microspheres Microspheres | Eudragit coating has successfully sustained the release of BDS in the upper GIT (pH 2.0 and 6.8) while providing the potential for efficient release of BDS in the colon (pH 7.4). | [58] [57]       |
| Vancomycin       | Chitosan-based micro and nanoparticles            | Site-specific and controlled delivery and reduce toxicity. Micro and nanoparticles improve the release in the colon. | [59] [60]       |
| Glucocorticoster | Collagen microparticles                           | The drug was not influenced by the pH of the release medium. Binding to the mucosa. | [61]            |
Role of probiotics in the treatment of ulcerative colitis

Probiotics are live microorganisms which when given in sufficient quantity, are beneficial to the host. Probiotics are microorganisms that we take into our bodies to support our health. Commonly, they’re strains of bacteria that can help improve our digestion. The health benefits of Probiotics are shown in fig. 5 [61]. Probiotics are that rare supplement from which almost everyone can benefit. Probiotics assist with a lot of health concerns, such as healthy digestion, healthy metabolism, and even increased weight loss. A poor diet, too much stress, and a lifetime of antibiotics have likely disposed of the majority of the good bacteria. The identification of the microbial environment and cytokine expression as key components of intestinal mucositis, probiotics represents a promising therapeutic option. When probiotics are administered in sufficient numbers, they can provide beneficial physiologic or therapeutic activities. Bacteria can be derived from various sources, such as cultured food and normal human microbiota, but must certain criteria included complete identification at genus, species, and strain level (antimicrobial substances; safety for consumption; may apply probiotic properties is impressive. Some are listed in table 4. For nutrition, the strains categorized as lactic acid bacteria are of importance, and out of them, are of genera Lactococcus and Bifidobacterium.

![Fig.5: Health benefits of probiotic](image)

**Table 4: Microorganisms commonly used as probiotics**

| Lactobacilli | Bifidobacteria | Others | References |
|--------------|----------------|--------|------------|
| L. Casei Shirotai | B. longum | Escherichia coli Nissle | [62] |
| L. rhamnosus GG | B. bifidum | Saccharomyces boulardii | |
| L. johnsonii | B. infantis | Enterococcus faecalis | |
| L. acidophilus | B. lactis | Lactococcus lactis | |
| L. gasseri | B. breve | Propionibacteria | |
| L. reuteri | B. animalis | | |
| L. casei | B. adolescentis | | |
| L. fermentum | | | |
| L. crispatus | | | |

**Lactobacilli** are Gram-positive, non-spore-forming, and non-flagellated rods or coccus bacilli, aerotolerant, fastidious, acid-tolerant, and strictly fermentative [63]. The different probiotic strain has different ability, even within the same species, it is different. Different strains of the same species are always distinct and may have different areas of attachment (site-specific), specific immunological effects, and activity on a healthy vs. an inflamed mucosal milieu may be different from each other. The research on probiotic today aims at the characterization of microbiota in each individual, analyzing the species composition as well as the number of different bacteria in the intestine. The objective is to learn to comprehend host-microbe interactions inside the gut, microbiome interactions inside the microbiota, and to learn the health effects of these interactions. The aim is to study the microbiota in the nutritional management of gut-related problems and as an origin of new microbes for future probiotic bacteriathapy applications. This will finally include organisms notably isolated to provide site-specific actions in disorders like IBD [64].

Probiotics alter the function of the mucosal immune system making it more anti-inflammatory and less pro-inflammatory. Especially, probiotics can inspire dendritic cells to make them less responsive and less reactive to bacteria within the lumen. Probiotics increase the production of mucus and the patient will finally have a thicker layer, which saves the invasive bacteria. Probiotics supplements may lower the side effect of individual drugs. Different Protective actions of probiotics show in table 5.

![Table 5: Protective action of probiotics](image)

| Microflora | Action of microflora | Reference |
|------------|---------------------|-----------|
| Bifidobacteria species | Reduced incidence of neonatal necrotizing enterocolitis | [66] |
| Lactobacillus strains | Balancing intestinal microflora, treatment of viral diarrhea | [67] |
| Lactobacillus Acidophilus | Improved mucosal immune function, mucin secretion, and prevention of disease. | |
| Lactobacillus Plantarum | Lactose digestion improved decreased diarrhea and symptoms of lactose intolerance individuals, children with diarrhoea, and in individuals with short-bowel syndrome. | |
| Lactobacillus rhamnosus | Significant decrease of diarrhea in patients receiving pelvic irradiation. | [68,69] |
| Lactobacillus rhamnosus | Lowered serum cholesterol levels; Reduced incidence of diarrhea in daycare centers when administered to only half of the children. | [70-72] |
| Lactobacillus rhamnosus | Especially effective in reducing inflammation in inflammatory bowel; enterocolitis in rats, small bowel bacterial overgrowth in children, pouchitis. Reduced pain and constipation of irritable bowel syndrome. | |
| Lactobacillus rhamnosus | Enhanced cellular immunity in healthy adults controlled trials. | [73] |
Probiotics and ulcerative colitis

*Escherichia coli* Nissle 1917 and *Saccharomyces boulardii* were used as probiotics. Probiotics have living microorganisms that provide health benefits to the host.*Escherichia coli* Nissle 1917 exhibited therapy with mesalamine in patients with ulcerative colitis. It was seen that the probiotic drug *E. coli*Nissle 1917 showed the effectiveness and was declared to be safe to maintain remission and was equal to mesalazine in patients with ulcerative colitis. The efficacy of probiotic therapy further tells about the pathogenic importance of the enteric flora [76].

Fábrega et al. (2017) have shown the intestinal Anti-inflammatory Effects from *Escherichia coli* Nissle 1917 in DSS-Experimental Colitis was studied in Mice. Oral administration of purified *E. coli* OMVs (5µg/day) significantly reduced DSS-induced weight loss and ameliorated clinical symptoms and histological scores. This study showed that E. coli OMVs can mediate the anti-inflammatory and barrier protection effects previously reported for this probiotic in experimental colitis [77].

Naidoo et al. (2011) Studies have shown the significance of intestinal bacterial flora in the pathogenesis of inflammatory bowel disease. It has therefore proposed that altering the bacterial flora with probiotics will reduce the inflammatory process and stop the relapses in ulcerative colitis (UC) [78].

Pronio et al. (2008) studies that show that the period, VSL#3-treated patients showed a notable loss in PDAI score and a major enhancement in the percentage of mucosal CD4CD25high and CD4 LAP-positive cells compared with baseline values. Different samples were taken at different points a significant reduction in IL-1 mRNA expression was seen, and a major enhancement in Fosp3 mRNA expression [79].

Zocco et al. (2006) were studied aminosalicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder. *Lactobacillus* GG looks to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients [80].

Loren et al. (2017) investigated the therapeutic benefits of *Lactobacillus Plantarum* (CCT7484, CCT74885) and *Pediococcus Acidilactici* (CCT7483) in a murine model of colitis. Result suggests that the selected probiotic group significantly reduces colitis severity compared to untreated controls [91].Wanget al. (2015) has studied the main mechanisms have not been completely explained; the antioxidant activity of probiotics seems to play an important role in reducing inflammation. Several studies have reported that probiotics particularly *Lactobacillus* species, exhibit strong antioxidant activity [82]. Chauhan et al. (2010) have recently, *Lactobacillusfermentum* has been studied for use as a supplement in the management of inflammatory bowel disease (IBD). Reinforcing the effects of *L. Fermentum* in inflammation, Chauhan and coworkers assessed its antioxidative efficacy in a colitis mouse model. Results proposed that the selected strain of *Lactobacillus* exhibits significant antioxidant activity. Also besides, probiotics seem to upregulate the level of antioxidant enzymes [83].

CONCLUSION

The current therapeutic goals are to achieve clinical remission along with mucosal healing, avoidance of complications such as side effects of the drug and to improve the quality of life. The use of probiotics to increase the health of the intestine and used to block or manage intestinal disorders. They may prevent the induction of inflammatory reactions. Probiotics must be inspected for efficacy in the prevention and management of a wide spectrum of gastrointestinal diseases, like antibiotic-associated diarrhea. There are many benefits to probiotics over conventional therapy, including various things like low cost, the fact that probiotics are improbable to enhance the incidence of antibiotic resistance, and the multiple methods by which probiotics stop pathogens, therefore limiting the chances for the development of resistance against the probiotic. At present, no microencapsulated probiotic cells exist in the market. Thus, the search is increasing on new delivery strategies that can provide therapeutic benefits to colitis sufferers. It has been concluded from the above study that micro and nanoparticulate carrier and probiotics system appears to be the most promising approach by specifically accumulating in the inflamed intestinal region.

FUNDING

Nil

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICTS OF INTERESTS

The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.

REFERENCES

1. Kaesam Z, Belga S, Roilman I, Hirota S, Jijon H, Kaplan GG, et al. Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm Bowel Dis 2014;12:2483-92.
2. Xavier RJ, Podolsky DK. Unraveling the pathogenesis of inflammatory bowel disease. Nature 2007;472:437-43.
3. Larmonier CB, Shehab KW, Ghishan FK, Kiela PR. T lymphocyte dynamics in inflammatory bowel diseases: role of the microbiome. Biomed Res Int 2015;2015:25.
4. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014;1:91.
5. Friend DR. New oral delivery systems for the treatment of inflammatory bowel disease. Adv Drug Delivery Rev2005;5:247-65.
6. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol2010;5:339.
7. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterology 2010;1:250-9.
8. Molodecky NA, Soon S, Kab I, Dhaliwal R, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;14:46-54.
9. Ungaro R, Chang HL, Cote Daigneaut J, Mehandru S, Atreja A, Colombel JF. Statins associated with decreased risk of new onset inflammatory bowel disease. Am J Gastroenterol 2016;10:1416.
10. Kim DH, Cheon JH. Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies. Immune Netw 2017;1:25-40.
11. Weinstock JV, Elliott DE. Helminths and the IBD hygiene hypothesis. Inflamm Bowel Dis 2008;1:128-33.
12. Porter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;5:1-16.
13. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer Lett 2014;2:235-41.
14. Navaneethan U, Jagadeesan R, Gutierrez NG, Venkatesh PG, Hammel JP, Shen B, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J CrohnsColitis 2013;12:684-91.
15. Botoman VA, Bonner GB, Botoman DA. Management of inflammatory bowel disease. Am Fam Physician 1998;1:57-68.
16. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest2007;3:14-21.
17. Ardizone S, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. Gen Intern Med2002;6:475-96.
18. Fuss I, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassic CD1d-restricted NK T cells that produce IL-
13 characterize an atypical Th2 response in ulcerative colitis. Int J Clin Invest 2004;10:1490-7.
19. Stein J, Ries J, Barnett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J PhysiolGastro Int 1998;1:G203-9.
20. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol2011;1:7:3204.
21. Taylor KM, Irving PM. Optimization of conventional therapy in patients with IBD. Nat Rev GastroenterolHepatol 2011;1:1:646.
22. ArdizzoneS, Porro GB. Inflammatory bowel disease: new insights into pathogenesis and treatment. Intern Med J 2002;6:475-96.
23. Feuerstein JD, Chefetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc2014;1:1:533-63.
24. Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. GastrointestPharmacol 2017;2:115-46.
25. Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Library2016;5. DOI:10.1002/14651858.CD000544.pub4
26. Probert CS, Dignass AU, Lindgren S, Oudkerk Pool M, Marteau P. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. J Crohns Colitis 2014;3:200-7.
27. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al.Glucocorticoid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;4:590.
28. Isaacs KL, Lewis JD, Sandborn WJ, Sands BE, Targan SR. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005;1:3:9-2.
29. Frei P, Biedermann L, Nielsen OH, Rogler G. Use of thiopurines in inflammatory bowel disease. World J Gastroenterol 2013;7:1040.
30. Abraham BP, Ahmed T, Ali T. Inflammatory bowel disease: pathophysiology and current therapeutic approaches. Gastrointestinal Pathology 2017;2:115-46.
31. GarbodP, Peppermann MA. Ulcerative colitis: current treatment strategies and future prospects. Ther AdvGastroenterol 2009;2:99-108.
32. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008;1:639-41.
33. Mackey AC, Green L, Liang LC, Dinning P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J PediatrGastroenterol Nutr 2007;2:265-7.
34. Meier J, Sturm A. Current treatment of ulcerative colitis. World J Gastroenterol2011;1:2:3204.
35. Kim KK, Pack DW. Microspheres for drug delivery. J Biomed Nanotechnol 2006;2:19-50.
36. Lee JK, Tang DH, Molonn L, Armstrong EP. Cost-effectiveness of biologics agents used in ulcerative colitis. Best Pract Res Clin Gastroenterol 2013;6:5:949-60.
37. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Joehns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;2:2462-76.
38. Papadakis KA, Shaye O, Skaalvolds OA, Ippoliti A, Dubinsky MC, Loane J, et al. Safety and efficacy of adalimumab (D277) in crohn’s disease patients with an attenuated response to infliximab Am J Gastroenterol 2005;1:7:5.
39. Sowmaya C, Reddy GS, Neelaboina VP. Colon specific drug delivery systems: A review on pharmaceutical approaches with current trends. Int Res J Pharm 2012;7:45-57.
40. Lautenschläger C, Schmitz C, Lehr CM, Fischer D, Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur J Pharm Biopharm 2013;3:578-86.
41. Talaei F, Atyabi F, Azhadzadeh M, Dinavand R, Saadat扎deh A. Overcoming therapeutic obstacles in inflammatory bowel diseases: a comprehensive review on novel drug delivery strategies. Eur J Pharm Sci 2013;4:7:12-22.
42. Collnot EM, Ali H, Lehr CM. Nano-and microparticle drug carriers for targeting of the inflamed intestinal mucosa. J Controlled Release 2012;2:235-46.
43. Youshij A, Lampricht A. Size-dependent nanoparticle drug delivery in inflammatory bowel diseases. Expert Opin Drug Delivery 2016;2:281-94.
44. Coppi G, Iannucci V, Bernabei MT, Camanelli R. Alginate microspheres for enzyme peroral administration. Int J Pharm 2002;6:63-9.
45. Lampricht A, Schafer U, Lehr CM. Size-dependent biodistribution of microparticles targeted to the inflamed colonic mucosa. J Pharm Res Int 2001;1:6788-93.
46. Lampricht AL, Ubirch N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, et al. Biodegradable nanoparticles for targeted drug delivery in inflammatory bowel disease. J Pharm Pharmacol 2011;1:775-81.
47. Duan H, Lu S, Qin H, Gao C, Bai X, Wei Y, et al. Co-delivery of zinc and 5-aminosalicylic acid from alginate/N-sucinyl-chitosan blend microspheres for synergistic therapy of colitis. Int J Pharm 2017;2:214-24.
48. Duan H, Lu S, Qin H, Gao C, Bai X, Wei Y, et al. Mucoadhesive microspheres based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon. Colloids Surf B 2016;9:510-9.
49. Mladenovska K, Kraudo O, Richomme P, Belami E, Raikki RS, Venierjulienne MC, et al. 5-ASA loaded chitosan–Ca–alginate nanoparticles: preparation and physicochemical characterization. Int J Pharm 2007;2:59-69.
50. Mura C, Nacher A, Merito V, Merito Sanjuan M, Manconi M, Loy G, et al. Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-sucinyl-chitosan microparticles for colon specific delivery. Colloids Surf B 2012;6:199-205.
51. Meiero A, Draheim C, Hansen S, Giner E, Carreras JJ, TalensVisconti R, et al. Targeted delivery of cyclosporine a by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur J Pharm Biopharm 2017;10:361-71.
52. Guiada M, Lana H, Gil AG, del Carmen Dios Veitez M, Blanco Prieto MJ. Cyclosporine a lipid nanoparticles for oral administration: pharmacokinetics and safety evaluation. Eur J Pharm Biopharm 2016;4:112-8.
53. Dai W, Gao Y, Zhang H, Wang X, Zhang Q. Systasis 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine a. Int J Pharm 2015;2:718-25.
54. Oseogi T, Oshichi H, Machida Y. Novel preparation of enteric-coated chitosan–sucinyl–prednisolone conjugate microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur J Pharm Biopharm 2008;2:260-6.
55. Zhang H, Shahbazi MA, Makila EM, da Silva TH, Reis RL, Salonen JJ, et al. Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisolone and mesalamine. Biomaterials 2013;3:12:9210-9.
56. Onooshii H, Oseogi T, Machida Y. Efficacy and toxicity of eudragit-coated chitosan–sucinyl–prednisolone conjugate microspheres using rats with 2, 4, 6-trinitrobenzenesulfonyl acid-induced colitis. Int J Pharm 2008;2:296-302.
57. Czarzewska MS, Dedov MG, Goracinova K. Chitosan coated Ca–alginiate microparticles loaded with budesonide for delivery to the inflamed colonic mucosa. Eur J Pharm Biopharm 2008;3:565-78.
58. Krishnamachary M, Madan P, Lin S. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm 2007;2:238-47.
59. Cerchiara T, Abruozza A, Di Cagno M, Bugucci F, Bauer Brandi A, Parolin C, et al. Chitosan based micro-and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. Eur J Pharm Biopharm 2015;5:112-9.
60. Derthold A, Cremer K, Kreuter J. Collagen micropraticles: carriers for glucocorticosteroids. Eur J Pharm Biopharm 1998;1:23-9.
61. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;6:1620-33.
62. Kechagia M, Basoulis D, Konstantopoulo S, Dimitriadi D, Gyftopoulo K, Skarmoutsou N, et al. Health benefits of probiotics: a review. ISRN Nutr 2013;1:DOI:10.5402/2013/481651.

63. Figueroa Gonzalez I, Cruz Guerrero A, Quijano G. The benefits of probiotics on human health. J Microbiol BiochemTechnol S 2010;4:413-34.

64. Bergmann KR, Liu SX, Tian R, Kushnir A, Turner JR, Li HL, et al. Bifidobacteria stabilize claudins at tight junctions and prevent intestinal barrier dysfunction in mouse necrotizing enterocolitis. Am J Pathol 2013;5:1595-606.

65. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. J Clin Nutr Metab 2014;5:761-7.

66. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. Probiotic administration in patients with ileal pouch–anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008;5:662-8.

67. Zocco MA, Dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;11:1567-74.

68. Loren V, Manye J, Fuentes MC, Cabre E, Ojanguren I, Espadaler J. Comparative effect of the I3.1 probiotic formula in two animal models of colitis. Probiotics Antimicrob Proteins 2017;1:71-80.

69. Wang BG, Xu HB, Xu F, Zeng ZL, Wei H. Efficacy of oral bifidobacteriumblidum ATCC 29521 on microflora and antioxidant in mice. Can J Microbiol 2015;5:3249-62.